Exploratory Study of Radium-223 and VEGF-Targeted Therapy in Patients With Metastatic Renal Cell Carcinoma and Bone Mets
Phase I Study of Radium-223 and Vascular Endothelial Growth Factor-Targeted Therapy in Patients With Metastatic Renal Cell Carcinoma and Bone Metastases
Sponsor: Bayer
Listed as NCT02406521, this PHASE1 trial focuses on Metastatic Renal Cell Carcinoma and remains completed. Sponsored by Bayer, it has been updated 11 times since 2015, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
11 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE1
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE1
-
Apr 2020 — Jan 2021 [monthly]
Completed PHASE1
Status: Active Not Recruiting → Completed
-
Jan 2020 — Apr 2020 [monthly]
Active Not Recruiting PHASE1
▶ Show 6 earlier versions
-
Mar 2019 — Jan 2020 [monthly]
Active Not Recruiting PHASE1
-
Jun 2018 — Mar 2019 [monthly]
Active Not Recruiting PHASE1
-
May 2018 — Jun 2018 [monthly]
Active Not Recruiting PHASE1
-
Aug 2017 — May 2018 [monthly]
Active Not Recruiting PHASE1
-
Feb 2017 — Aug 2017 [monthly]
Active Not Recruiting PHASE1
-
Jan 2017 — Feb 2017 [monthly]
Active Not Recruiting PHASE1
First recorded
Apr 2015
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Bayer
- Dana-Farber Cancer Institute
For direct contact, visit the study record on ClinicalTrials.gov .